<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00705783</url>
  </required_header>
  <id_info>
    <org_study_id>31-07-246</org_study_id>
    <nct_id>NCT00705783</nct_id>
  </id_info>
  <brief_title>Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia</brief_title>
  <acronym>ASPIRE</acronym>
  <official_title>A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an
      intramuscular depot formulation of aripiprazole as maintenance treatment in patients with
      schizophrenia.

      The trial was designed into 4 treatment phases. Phase 1 was designed to allow for a patient
      to be converted from their current antipsychotic treatment to oral non-generic aripiprazole
      monotherapy (oral conversion phase from 4 to 6 weeks). During Phase 2, the patient was
      stabilized on oral non-generic aripiprazole monotherapy (oral stabilization phase from a
      minimum of 4 weeks to a maximum of 12 weeks). Once the patient was stabilized in Phase 2,
      they entered Phase 3, the single-blind intramuscular (IM) depot aripiprazole stabilization
      phase. The goal of the phase was to stabilize the patient on the IM depot aripiprazole
      formulation for a minimum of 12 weeks to a maximum of 36 weeks. When the patient was
      stabilized, they were eligible to be randomized into the double-blind IM depot maintenance
      phase (Phase 4). During Phase 4, the patient was assessed for exacerbation of psychotic
      symptoms and/or impending relapse for up to 52 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double-blind, placebo-controlled study consisting of a screening phase
      and 4 treatment phases. Eligibility was determined during a screening phase of 2 to 42 days.
      Patients receiving oral treatment with an antipsychotic other than non-generic aripiprazole
      entered Phase 1. Patients with a lapse in aripiprazole or other antipsychotic treatment at
      the time of study entry (&quot;lapse&quot; defined as &gt; 3 consecutive days without medication) entered
      directly into Phase 2. During Phase 1 (oral conversion), patients were cross-titrated during
      weekly visits from other antipsychotics to oral non-generic aripiprazole monotherapy over a
      minimum of 4 weeks and a maximum of 6 weeks. During Phase 2 (a minimum of 4 weeks and a
      maximum of 12 weeks in duration), patients were assessed bi-weekly and stabilized on an oral
      dose of aripiprazole ranging from 10 mg to 30 mg daily. After stability criteria were met in
      Phase 2, patients entered the single-blind aripiprazole intramuscular (IM) depot
      stabilization phase, Phase 3. In Phase 3, patients were stabilized on aripiprazole IM depot
      for 12 consecutive weeks. Once the patient met the stability criteria, they were eligible to
      be randomized into the double-blind phase, Phase 4. Patients were randomized in a 2:1 ratio
      (aripiprazole IM depot vs placebo IM depot) stratified by region and last aripiprazole IM
      depot injection dose level in Phase 3. During Phase 4, patients were assessed for impending
      relapse/exacerbation of psychotic symptoms. If a patient was identified with impending
      relapse/exacerbation of psychotic symptoms, they were withdrawn from the trial and given the
      opportunity to enroll into an open-label aripiprazole IM depot trial, 31-08-248. Patients
      that completed Phase 4 (up to and including Week 52) had the option to enroll into an
      open-label aripiprazole IM depot trial, 31-08-248 (NCT00731549).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Exacerbation of Psychotic Symptoms/Impending Relapse</measure>
    <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
    <description>A patient experienced an exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score ≥ 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score &gt; 4 with an increase of ≥ 2 on that item since randomization or an increase on any of the same PANSS items to a score &gt; 4 and an increase of ≥ 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria</measure>
    <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
    <description>This is the key secondary Outcome Measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders</measure>
    <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
    <description>A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score ≤ 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) ≤ 4 (moderately ill) and 5) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Remission</measure>
    <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
    <description>A patient was considered to have achieved remission if they had a score of ≤ 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the PANSS Total Score</measure>
    <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
    <description>The PANSS consists of 3 subscales (Positive Subscale, 7 constructs, scores ranged from 7-49, Negative Subscale, 7 constructs, scores ranged from 7-49, General Psychopathology Subscale, 16 constructs, scores ranged from 16-112) containing a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. The PANSS total score ranged from 30-210 with a higher score indicating more severe symptoms. A negative change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score</measure>
    <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
    <description>The severity of illness for each patient was rated using the CGI-S. To assess CGI-S, the rater or investigator answered the following question: &quot;Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?&quot; Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The CGI-S score ranged from 0-7 with a higher score indicating greater illness. A negative change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the PANSS Positive Subscale Score</measure>
    <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
    <description>The PANSS Positive Subscale consists of 7 symptom constructs (delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the PANSS Negative Subscale Score</measure>
    <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
    <description>The PANSS Negative Subscale consists of 7 symptom constructs (blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Clinical Global Impression-Improvement (CGI-I) Score</measure>
    <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
    <description>The efficacy of the study medication was rated for each patient using the CGI-I scale. The rater or investigator rated the patient's total improvement whether or not it was due entirely to drug treatment. All responses were compared to the patient's condition at Baseline. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I score ranged from 0-7 with a higher score indicating less improvement/worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discontinuation</measure>
    <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
    <description>Time to discontinuation was defined as the date of randomization to the date of study discontinuation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">843</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Aripiprazole depot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo depot</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received placebo intramuscularly every 28 days for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole depot</intervention_name>
    <description>Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.</description>
    <arm_group_label>Aripiprazole depot</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo depot</intervention_name>
    <description>Placebo depot was supplied in 400 mg lyophilized vials.</description>
    <arm_group_label>Placebo depot</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are able to provide written informed consent and/or consent obtained from
             a legally acceptable representative (as required by the Institutional Review
             Board/Institutional Ethics Committee [IRB/IEC]), prior to the initiation of any
             protocol-required procedures.

          -  Male and female subjects 18 to 60 years of age, inclusive, at time of informed
             consent.

          -  Subjects with a current diagnosis of schizophrenia as defined by Diagnostic and
             Statistical Manual of Mental Disorders, 4th edition text revision (DSM-IV-TR) criteria
             and a history of the illness for at least 3 years prior to screening.

          -  Subjects who, in the investigator's judgment, require chronic treatment with an
             antipsychotic medication.

          -  Subjects able to understand the nature of the study and follow protocol requirements,
             including the prescribed dosage regimens, tablet ingestion, IM depot injection,
             discontinuation of prohibited concomitant medications; who can read and understand the
             written word in order to complete patient-reported outcomes measures; and who can be
             reliably rated on assessment scales.

        Exclusion Criteria:

          -  Subjects with a current DSM-IV-TR diagnosis other than schizophrenia, including
             schizoaffective disorder, major depressive disorder, bipolar disorder, delirium,
             dementia, or amnestic or other cognitive disorders. Also, subjects with borderline,
             paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.

          -  Subjects with schizophrenia that are considered resistant/refractory to antipsychotic
             treatment by history or response only to clozapine.

          -  Subjects with a significant risk of violent behavior or a significant risk of
             committing suicide based on history or investigator's judgment.

          -  Subjects who currently meet DSM-IV-TR criteria for substance dependence, including
             alcohol and benzodiazepines, but excluding caffeine and nicotine; or 2 positive drug
             screens for cocaine.

          -  Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment
             with aripiprazole or other quinolinones; or hypersensitivity to antipsychotic agents.

          -  Subjects with uncontrolled thyroid function abnormalities.

          -  Subjects with a history of seizures, neuroleptic malignant syndrome, clinically
             significant tardive dyskinesia, or other medical condition that would expose them to
             undue risk or interfere with study assessments.

          -  Subjects who are involuntary incarcerated.

          -  Subjects who have used an investigational agent within 30 days of screening or prior
             participation in a clinical study with aripiprazole IM depot.

          -  Subjects with clinically significant abnormalities in laboratory test results, vital
             signs, or ECG results; and subjects hospitalized for more than 30 days in the 90 days
             prior to Phase 1.

          -  Subjects who fail to wash-out from prohibited concomitant medications, including the
             use of CYP2D6 or CYP3A4 inhibitors or CYP3A4 inducers, antipsychotics, antidepressants
             (including monoamine oxidase inhibitors [MAOI}), and mood stabilizers during screening
             and/or Phase 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Sanchez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Highlands Ranch</city>
        <state>Colorado</state>
        <zip>80130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>North Platte</city>
        <state>Nebraska</state>
        <zip>69101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <zip>11516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Elmsford</city>
        <state>New York</state>
        <zip>10523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Holliswood</city>
        <state>New York</state>
        <zip>11423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Bothell</city>
        <state>Washington</state>
        <zip>98011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Bs. As.</city>
        <state>Buenos Aires</state>
        <zip>C1058AAJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Lanús Este</city>
        <state>Buenos Aires</state>
        <zip>B1834IBR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Pueyrredón</city>
        <state>Cordoba</state>
        <zip>X5004ALB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405BOA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425AHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5009BIN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500HYF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Lovech</city>
        <zip>5500</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Radnevo</city>
        <zip>6260</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Region of Veliko Tarnovo</city>
        <zip>5047</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Rousse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Kanpur</city>
        <zip>208005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Mangalore</city>
        <zip>575018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Pune</city>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Tirupati</city>
        <zip>517507</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Cheras</city>
        <state>Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Tanjong Rambutan</city>
        <state>Perak</state>
        <zip>31250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Wilayah Persekutuan</state>
        <zip>50603</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Selangor</city>
        <zip>43000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>6700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64040</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Culiacan</city>
        <state>Sinaloa</state>
        <zip>80020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>San Luis Potosí</city>
        <zip>78218</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Bataan</city>
        <state>Central Luzon</state>
        <zip>2105</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Mandaluyong</city>
        <state>NCR</state>
        <zip>1553</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <state>NCR</state>
        <zip>1104</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Iloilo</city>
        <state>Western Visayas</state>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Arad</city>
        <zip>310022</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>041914</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400012</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Craiova</city>
        <zip>200620</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Oradea</city>
        <zip>410154</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Pitesti</city>
        <zip>110069</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Lipetsk</city>
        <zip>399083</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115409</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603107</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>188357</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Kosice</city>
        <zip>041 90</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Liptovský Mikuláš</city>
        <zip>031 23</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Presov</city>
        <zip>081 81</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Rimavská Sobota</city>
        <zip>979 12</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Svidnik</city>
        <zip>089 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Hualien</city>
        <zip>981</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>India</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Lithuania</country>
    <country>Peru</country>
    <country>Ukraine</country>
  </removed_countries>
  <results_reference>
    <citation>Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, McQuade RD, Carson WH, Fleischhacker WW. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012 May;73(5):617-24. doi: 10.4088/JCP.11m07530.</citation>
    <PMID>22697189</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2008</study_first_submitted>
  <study_first_submitted_qc>June 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2008</study_first_posted>
  <results_first_submitted>March 29, 2013</results_first_submitted>
  <results_first_submitted_qc>June 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 19, 2013</results_first_posted>
  <disposition_first_submitted>September 2, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>September 2, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 12, 2011</disposition_first_posted>
  <last_update_submitted>June 16, 2013</last_update_submitted>
  <last_update_submitted_qc>June 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aripiprazole</keyword>
  <keyword>Intramuscular (IM) depot</keyword>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were 4 phases in this study. In phases 1-3 (Conversion Phase, Oral Stabilization Phase, Depot Stabilization Phase), there was a single treatment group. In phase 4 (Depot Maintenance Phase), there were 2 treatment groups. All Outcome Measures were assessed in the Depot Maintenance Phase of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Patients</title>
          <description>During the Conversion Phase, patients were cross-titrated from other antipsychotics to oral non-generic aripiprazole monotherapy. During the Oral Stabilization Phase, patients were stabilized on an oral dose of aripiprazole ranging from 10 mg to 30 mg daily. During the Depot Stabilization Phase, patients were stabilized on aripiprazole depot.</description>
        </group>
        <group group_id="P2">
          <title>Aripiprazole Depot</title>
          <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo Depot</title>
          <description>Patients received placebo intramuscularly every 28 days for 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Conversion Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="633"/>
                <participants group_id="P2" count="0">There were no patients in this reporting group in this phase of the study.</participants>
                <participants group_id="P3" count="0">There were no patients in this reporting group in this phase of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Medication</title>
              <participants_list>
                <participants group_id="P1" count="632"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor Discontinued Study</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Withdrawal Criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn by Investigator</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy with Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy without Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Oral Stabilization Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="710">210 of the 710 patients who started this phase enrolled in this study directly into this phase.</participants>
                <participants group_id="P2" count="0">There were no patients in this reporting group in this phase of the study.</participants>
                <participants group_id="P3" count="0">There were no patients in this reporting group in this phase of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Medication</title>
              <participants_list>
                <participants group_id="P1" count="709"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="576"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor Discontinue Study</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Withdrawal Criteria</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn by Investigator</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy with Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy without Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Depot Stabilization Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="576"/>
                <participants group_id="P2" count="0">There were no patients in this reporting group in this phase of the study.</participants>
                <participants group_id="P3" count="0">There were no patients in this reporting group in this phase of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="403"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor Discontinued Study</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Withdrawal Criteria</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn by Investigator</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy with Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy without Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Depot Maintenance Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Patients were randomized into the aripiprazole and placebo depot groups in this phase of the study.</participants>
                <participants group_id="P2" count="269"/>
                <participants group_id="P3" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="246"/>
                <participants group_id="P3" count="131"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor Discontinued Study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="179"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Withdrawal Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn by Investigator</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event without Impending Relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Impending Relapse with Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Impending Relapse without Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline measures are based on the participants from the Depot Maintenance Phase.</population>
      <group_list>
        <group group_id="B1">
          <title>Aripiprazole Depot</title>
          <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Depot</title>
          <description>Patients received placebo intramuscularly every 28 days for 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="269"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="403"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.1" spread="11.0"/>
                    <measurement group_id="B2" value="41.7" spread="10.5"/>
                    <measurement group_id="B3" value="40.6" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Exacerbation of Psychotic Symptoms/Impending Relapse</title>
        <description>A patient experienced an exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score ≥ 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score &gt; 4 with an increase of ≥ 2 on that item since randomization or an increase on any of the same PANSS items to a score &gt; 4 and an increase of ≥ 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.</description>
        <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
        <population>Intent-to-treat population: All randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Depot</title>
            <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Depot</title>
            <description>Patients received placebo intramuscularly every 28 days for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Exacerbation of Psychotic Symptoms/Impending Relapse</title>
          <description>A patient experienced an exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score ≥ 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score &gt; 4 with an increase of ≥ 2 on that item since randomization or an increase on any of the same PANSS items to a score &gt; 4 and an increase of ≥ 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.</description>
          <population>Intent-to-treat population: All randomized patients.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median and confidence interval were not estimable due to too few events.</measurement>
                    <measurement group_id="O2" value="209" lower_limit="161" upper_limit="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Based on 6-month IR rates of 55% for placebo and 35% for aripiprazole, sample sizes were estimated to achieve 90% power to detect a hazard ratio of 0.54 and to preserve an overall nominal alpha level of 0.05 (2-sided), allowing for 2 interim looks at 50% and 75% of events. Assuming that each subject was followed for 12 months after randomization and allowing for a 25% loss to follow-up, the projected total number of subjects to be randomly assigned to treatment in the trial was 225.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.199</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.125</ci_lower_limit>
            <ci_upper_limit>0.317</ci_upper_limit>
            <estimate_desc>Aripiprazole depot/placebo depot</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria</title>
        <description>This is the key secondary Outcome Measure.</description>
        <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
        <population>Intent-to-treat population: All randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Depot</title>
            <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Depot</title>
            <description>Patients received placebo intramuscularly every 28 days for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria</title>
          <description>This is the key secondary Outcome Measure.</description>
          <population>Intent-to-treat population: All randomized patients.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The alpha levels for this key secondary Outcome Measure were the same as used for the primary Outcome Measure.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders</title>
        <description>A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score ≤ 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) ≤ 4 (moderately ill) and 5) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.</description>
        <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
        <population>Intent-to-treat (ITT) population: All randomized patients. Two of the 269 patients in the ITT population did not attend the Last Visit at which this Outcome Measure was assessed and were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Depot</title>
            <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Depot</title>
            <description>Patients received placebo intramuscularly every 28 days for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders</title>
          <description>A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score ≤ 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) ≤ 4 (moderately ill) and 5) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.</description>
          <population>Intent-to-treat (ITT) population: All randomized patients. Two of the 269 patients in the ITT population did not attend the Last Visit at which this Outcome Measure was assessed and were not included in the analysis.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.6"/>
                    <measurement group_id="O2" value="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Remission</title>
        <description>A patient was considered to have achieved remission if they had a score of ≤ 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).</description>
        <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
        <population>Intent-to-treat population: All randomized patients who stayed in Phase 4 for at least 6 months and had values for the specific PANSS items P1, G9, P3, P2,G5, N1, N4, and N6.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Depot</title>
            <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Depot</title>
            <description>Patients received placebo intramuscularly every 28 days for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Remission</title>
          <description>A patient was considered to have achieved remission if they had a score of ≤ 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).</description>
          <population>Intent-to-treat population: All randomized patients who stayed in Phase 4 for at least 6 months and had values for the specific PANSS items P1, G9, P3, P2,G5, N1, N4, and N6.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9"/>
                    <measurement group_id="O2" value="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1756</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the PANSS Total Score</title>
        <description>The PANSS consists of 3 subscales (Positive Subscale, 7 constructs, scores ranged from 7-49, Negative Subscale, 7 constructs, scores ranged from 7-49, General Psychopathology Subscale, 16 constructs, scores ranged from 16-112) containing a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. The PANSS total score ranged from 30-210 with a higher score indicating more severe symptoms. A negative change score indicates improvement.</description>
        <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
        <population>Intent-to-treat population: All randomized patients who had PANSS total scores at both baseline and at least 1 post-baseline time point in Phase 4. Last observation carried forward was implemented to impute the missing data at post-baseline visits. Baseline was not carried forward in imputing the missing data at post-baseline visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Depot</title>
            <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Depot</title>
            <description>Patients received placebo intramuscularly every 28 days for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the PANSS Total Score</title>
          <description>The PANSS consists of 3 subscales (Positive Subscale, 7 constructs, scores ranged from 7-49, Negative Subscale, 7 constructs, scores ranged from 7-49, General Psychopathology Subscale, 16 constructs, scores ranged from 16-112) containing a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. The PANSS total score ranged from 30-210 with a higher score indicating more severe symptoms. A negative change score indicates improvement.</description>
          <population>Intent-to-treat population: All randomized patients who had PANSS total scores at both baseline and at least 1 post-baseline time point in Phase 4. Last observation carried forward was implemented to impute the missing data at post-baseline visits. Baseline was not carried forward in imputing the missing data at post-baseline visits.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.756"/>
                    <measurement group_id="O2" value="11.55" spread="1.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA included treatment as a term and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.68</ci_lower_limit>
            <ci_upper_limit>-7.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score</title>
        <description>The severity of illness for each patient was rated using the CGI-S. To assess CGI-S, the rater or investigator answered the following question: “Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?” Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The CGI-S score ranged from 0-7 with a higher score indicating greater illness. A negative change score indicates improvement.</description>
        <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
        <population>Intent-to-treat population: All randomized patients who had CGI-S scores at both baseline and at least 1 post-baseline time point in Phase 4. Last observation carried forward was implemented to impute the missing data at post-baseline visits. Baseline was not carried forward in imputing the missing data at post-baseline visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Depot</title>
            <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Depot</title>
            <description>Patients received placebo intramuscularly every 28 days for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score</title>
          <description>The severity of illness for each patient was rated using the CGI-S. To assess CGI-S, the rater or investigator answered the following question: “Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?” Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The CGI-S score ranged from 0-7 with a higher score indicating greater illness. A negative change score indicates improvement.</description>
          <population>Intent-to-treat population: All randomized patients who had CGI-S scores at both baseline and at least 1 post-baseline time point in Phase 4. Last observation carried forward was implemented to impute the missing data at post-baseline visits. Baseline was not carried forward in imputing the missing data at post-baseline visits.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.051"/>
                    <measurement group_id="O2" value="0.66" spread="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA included treatment as a term and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the PANSS Positive Subscale Score</title>
        <description>The PANSS Positive Subscale consists of 7 symptom constructs (delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.</description>
        <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
        <population>Intent-to-treat population: All randomized patients who had PANSS sub-scale scores at both baseline and at least 1 post-baseline time point in Phase 4. Last observation carried forward was implemented to impute the missing data at post-baseline visits. Baseline was not carried forward in imputing the missing data at post-baseline visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Depot</title>
            <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Depot</title>
            <description>Patients received placebo intramuscularly every 28 days for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the PANSS Positive Subscale Score</title>
          <description>The PANSS Positive Subscale consists of 7 symptom constructs (delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.</description>
          <population>Intent-to-treat population: All randomized patients who had PANSS sub-scale scores at both baseline and at least 1 post-baseline time point in Phase 4. Last observation carried forward was implemented to impute the missing data at post-baseline visits. Baseline was not carried forward in imputing the missing data at post-baseline visits.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.265"/>
                    <measurement group_id="O2" value="4.25" spread="0.374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Positive Subscale Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA included treatment as a term and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.72</ci_lower_limit>
            <ci_upper_limit>-2.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the PANSS Negative Subscale Score</title>
        <description>The PANSS Negative Subscale consists of 7 symptom constructs (blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.</description>
        <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
        <population>Intent-to-treat population: All randomized patients who had PANSS sub-scale scores at both baseline and at least 1 post-baseline time point in Phase 4. Last observation carried forward was implemented to impute the missing data at post-baseline visits. Baseline was not carried forward in imputing the missing data at post-baseline visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Depot</title>
            <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Depot</title>
            <description>Patients received placebo intramuscularly every 28 days for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the PANSS Negative Subscale Score</title>
          <description>The PANSS Negative Subscale consists of 7 symptom constructs (blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking). For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Scores on each subscale ranged from 7-49 with a higher score indicating more severe symptoms. A negative change score indicates improvement.</description>
          <population>Intent-to-treat population: All randomized patients who had PANSS sub-scale scores at both baseline and at least 1 post-baseline time point in Phase 4. Last observation carried forward was implemented to impute the missing data at post-baseline visits. Baseline was not carried forward in imputing the missing data at post-baseline visits.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.201"/>
                    <measurement group_id="O2" value="1.55" spread="0.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA included treatment as a term and baseline as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.04</ci_lower_limit>
            <ci_upper_limit>-0.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Clinical Global Impression-Improvement (CGI-I) Score</title>
        <description>The efficacy of the study medication was rated for each patient using the CGI-I scale. The rater or investigator rated the patient’s total improvement whether or not it was due entirely to drug treatment. All responses were compared to the patient’s condition at Baseline. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I score ranged from 0-7 with a higher score indicating less improvement/worsening.</description>
        <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
        <population>Intent-to-treat population: All randomized patients who had CGI-I scores at both baseline and at least 1 post-baseline time point in Phase 4. Last observation carried forward was implemented to impute the missing data at post-baseline visits. Baseline was not carried forward in imputing the missing data at post-baseline visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Depot</title>
            <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Depot</title>
            <description>Patients received placebo intramuscularly every 28 days for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Clinical Global Impression-Improvement (CGI-I) Score</title>
          <description>The efficacy of the study medication was rated for each patient using the CGI-I scale. The rater or investigator rated the patient’s total improvement whether or not it was due entirely to drug treatment. All responses were compared to the patient’s condition at Baseline. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I score ranged from 0-7 with a higher score indicating less improvement/worsening.</description>
          <population>Intent-to-treat population: All randomized patients who had CGI-I scores at both baseline and at least 1 post-baseline time point in Phase 4. Last observation carried forward was implemented to impute the missing data at post-baseline visits. Baseline was not carried forward in imputing the missing data at post-baseline visits.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" spread="1.05"/>
                    <measurement group_id="O2" value="4.53" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discontinuation</title>
        <description>Time to discontinuation was defined as the date of randomization to the date of study discontinuation.</description>
        <time_frame>Baseline of the depot maintenance phase to the end of the study (Week 52)</time_frame>
        <population>Intent-to-treat population: All randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Depot</title>
            <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Depot</title>
            <description>Patients received placebo intramuscularly every 28 days for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discontinuation</title>
          <description>Time to discontinuation was defined as the date of randomization to the date of study discontinuation.</description>
          <population>Intent-to-treat population: All randomized patients.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="364">The median and the upper limit of the confidence interval were not estimable due to too few events.</measurement>
                    <measurement group_id="O2" value="162" lower_limit="98" upper_limit="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from the time of the signing of informed consent until the end of the study (up to 106 weeks).</time_frame>
      <desc>Safety population: All subjects who received at least 1 dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Conversion Phase</title>
          <description>During the Conversion Phase, patients were cross-titrated from other antipsychotics to oral non-generic aripiprazole monotherapy.</description>
        </group>
        <group group_id="E2">
          <title>Oral Stabilization Phase</title>
          <description>During the Oral Stabilization Phase, patients were stabilized on an oral dose of aripiprazole ranging from 10 mg to 30 mg daily.</description>
        </group>
        <group group_id="E3">
          <title>Depot Stabilization Phase</title>
          <description>During the IM Depot Stabilization Phase, patients were stabilized on aripiprazole IM depot.</description>
        </group>
        <group group_id="E4">
          <title>Aripiprazole Depot - Depot Maintenance Phase</title>
          <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Placebo Depot - Depot Maintenance Phase</title>
          <description>Patients received placebo intramuscularly every 28 days for 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Schizophrenia, paranoid type</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Psychiatric symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="184" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="103" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="632"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="709"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="576"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="269"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Affairs</name_or_title>
      <organization>Otsuka Pharmaceutical Development and Commercialization</organization>
      <phone>800 562-3974</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

